MyoKardia Gets $38M For Heart Disease Treatment

San Francisco-based Myokardia, a newly formed developer of small molecule therapeutics, said today that it is targeting genetic heart disease with $38M in funding. The Series A funding came from Third Rock Ventures. MyoKardia is developing treatments for hypertrophic and dilated cardiomyopathy. More information »